Deutsche Bank
TVTX icon

Deutsche Bank’s Travere Therapeutics TVTX Stock Holding History

Deutsche Bank’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-450
Closed -$5K – 5918
2014
Q4 		$5K Hold
450
– – ﹤0.01% 5883
2014
Q3 		$4K Buy
+450
New +$5.29K ﹤0.01% 5576

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's TVTX Position: Q2 2026 in Review

Deutsche Bank reduced its Travere Therapeutics (TVTX) stake by 76% in Q2 2026, selling an estimated $31.1M and leaving 225,583 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #989.

Deutsche Bank first reported a position in TVTX in Q1 2014 and has held it in 50 quarters since. The position peaked at $38.2M in Q3 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Deutsche Bank held 225,583 shares of Travere Therapeutics worth $12.8M as of Q2 2026.
  • Deutsche Bank sold 700,336 Travere Therapeutics shares in Q2 2026, an estimated $31.1M.
  • Travere Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #989 holding.
  • Deutsche Bank first reported a position in Travere Therapeutics in Q1 2014 and has held it in 50 quarters since.
  • Deutsche Bank's Travere Therapeutics position peaked at $38.2M in Q3 2025.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.